Financial Performance - Q3 2025 - Bio-Rad's Q3 2025 GAAP revenue was $653 million, with a gross margin of 52.6% and an operating margin of 10.0%[6] - The company's Q3 2025 GAAP net cash from operations was $121 million[6] - Bio-Rad's Q3 2025 non-GAAP revenue was also $653 million, with a gross margin of 53.5% and an operating margin of 11.8%[7] - The company's Q3 2025 non-GAAP free cash flow was $89 million[7] Segment and Geographic Revenue Mix - Q3 2025 - Clinical Diagnostics accounted for 60% of the company's revenue, while Life Science accounted for 40%[10] - Americas contributed 47% of the company's revenue, EMEA 34%, and APAC 19%[10] - Life Science Group revenue was $262 million[12, 13] - Clinical Diagnostics Group revenue was $391 million[14] Balance Sheet Highlights - September 30, 2025 - The company's cash and short-term investments totaled $1.419 billion[15] - Long-term debt stood at $1.201 billion[15] - Investment in Sartorius AG was $4.643 billion[15] Full-Year 2025 Outlook - The company maintains its full-year 2025 outlook for currency neutral revenue growth of 0.0% to +1.0%[16] - The company anticipates free cash flow between $310 million and $330 million[16]

2025 Third Quarter Financial Results Our Mission: Protect and Save Lives October 29, 2025 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and ear ...

INVESTOR PRESENTATION Q3'25 Results October 29, 2025 DISCLAIMERS MercadoLibre, Inc. I 2 IR CONTENT Third Quarter 2025 This presentation may contain forward-looking statements including, but not limited to, statements regarding MercadoLibre, Inc.'s expectations, objectives and progress against strategic priorities; initiatives and strategies related to our products and services; our inability to successfully deliver new products and services; business and market outlook, opportunities, strategies and trends; ...

Q3 2025 Highlights - Total revenue reached $89.8 million, a 2.5% year-over-year increase[4] - Adjusted EBITDA grew by 11.8% year-over-year to $29.7 million[4] - Adjusted EBITDA margin expanded by 300 basis points to 33%[4] Glo Fiber Expansion Markets - Glo Fiber expansion markets passed 400,000 locations, with 21,000 released to sales[4] - Data RGUs (Revenue Generating Units) in Glo Fiber expansion markets increased by 39.5% annually[4] - Glo Fiber expansion markets revenue grew by 41.1% annually[4,31] - Year-over-year RGU growth was +37%[8] - Vintage Glo Fiber Expansion Markets Penetration is expected to reach an average terminal penetration of 37%[13] Incumbent Broadband Markets - Approximately 70% of incumbent broadband markets passings have no competitor[5] - Approximately 20% of passings in incumbent broadband markets have FTTH (Fiber to the Home)[18] - Average penetration in Incumbent Broadband Markets Subsidy Cohort is 30%[21] Financial Outlook - The company projects total revenue between $352 million and $357 million for the year ending December 31, 2025, representing an 8.1% increase at the midpoint compared to 2024[38] - Adjusted EBITDA is projected to be between $113 million and $118 million, a 21.6% increase at the midpoint[38]

Offering everyone a piece of the American spirit—one handshake at a time. Supplemental Financial Presentation October 2025 0 Important Information Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this presentation are forward- looking statements. Forward-looking statements refer to the Boot Barn Holdings, Inc.'s (the "Company," "Boot Barn," "BOOT," "we," "us," and ...

Q3 2025 Performance - Product revenue reached $87.7 million, representing a 33.1% year-over-year growth but an 8.8% decrease compared to the previous quarter[3] - Total revenue for Q3 2025 was $143.8 million, a 32.2% increase year-over-year but an 8.6% decrease quarter-over-quarter[4] - Service revenue amounted to $56.1 million, showing a 30.9% year-over-year growth but an 8.4% decrease from the previous quarter[5] - Net income for Q3 2025 was $24.3 million, a significant increase of $20.1 million year-over-year but a decrease of $10.6 million quarter-over-quarter[5] - Total cash reached $466.2 million, an increase of $65.6 million quarter-over-quarter[5] Revenue Breakdown by Organ - Liver revenue was $107.94 million, a 40.8% increase year-over-year but a 7.0% decrease quarter-over-quarter[11, 16] - Heart revenue was $30.589 million, a 13.6% increase year-over-year and a 14.2% decrease quarter-over-quarter[11, 16] - Lung revenue was $4.11 million, a 5.2% increase year-over-year and a 10.2% decrease quarter-over-quarter[11, 16] Service Revenue Details - Clinical service revenue decreased by 8.7% quarter-over-quarter but increased by 29.0% year-over-year[14] - Logistics revenue decreased by 8.9% quarter-over-quarter but increased by 35.2% year-over-year[14] - Flight school revenue increased by 15.7% quarter-over-quarter but decreased by 5.7% year-over-year[14] Financial Metrics - Gross margin for Q3 2025 was 58.8%, a 2.9 percentage point increase year-over-year but a 2.6 percentage point decrease quarter-over-quarter[4] - Operating margin for Q3 2025 was 16.2%, a 12.6 percentage point increase year-over-year[4] Updated 2025 Revenue Guidance - The company updated its total revenue guidance for 2025 to a range of $595 million to $605 million, projecting a 36% growth at the midpoint of the range[20]

Financial Performance Highlights - Revenue reached $299.1 million, exceeding the high end of guidance, a 25.6% year-over-year increase[7, 17] - Non-GAAP Operating Income was $47.1 million, also above the high end of guidance, with a Non-GAAP Operating Margin of 15.7%[7] - Non-GAAP EPS was $0.15, a 150% year-over-year increase[7] - The company generated $31.0 million in operating cash flow and $22.5 million in free cash flow[8] Segment Performance - Network and Service Enablement (NSE) revenue was $216.0 million, up 35.5% year-over-year, driven by strong demand from the data center ecosystem and growth in aerospace and defense products[11] - Optical Security and Performance Products (OSP) revenue was $83.1 million, a 5.5% year-over-year increase, primarily due to strength in Anti Counterfeiting and Other products[13] - NSE Gross Margin increased to 63.0%, up 210 basis points year-over-year, while OSP Gross Margin decreased to 52.3%, down 300 basis points year-over-year[11, 13] Capital Allocation and Outlook - The company successfully closed the acquisition of Spirent's high-speed ethernet, network security, and channel emulation business lines from Keysight, expected to add about $200 million of annual revenue run rate[9] - Refinanced $250 million of 1.625% convertible notes due in March 2026 with $250 million of 0.625% convertible notes due in March 2031[9] - The business outlook for Fiscal Q2 2026 includes revenue between $360 million and $370 million and Non-GAAP EPS between $0.18 and $0.20[14]

Trial Results - TX45 was well-tolerated in patients with PH-HFrEF in a single-dose study[6, 17] - The trial observed improvements in left ventricular function and pulmonary hemodynamics in PH-HFrEF, consistent with effects demonstrated in the PH-HFpEF study[6, 23] - In PH-HFrEF patients, TX45 led to a mean reduction of 64 mm Hg (292%) in PCWP (Pulmonary Capillary Wedge Pressure)[18] - In CpcPH patients (PVR ≥ 3 WU), TX45 resulted in a mean reduction of 110 WU (197%) in PVR (Pulmonary Vascular Resistance)[18] - Cardiac Output (CO) increased by a mean of 065 L/min (173%) in all participants[18] - Stroke Volume (SV) increased by a mean of 68 mL (134%) in all participants[18] - Total Pulmonary Resistance (TPR) decreased by a mean of 282 WU (292%) in all participants[18] - Mean Pulmonary Artery Pressure (mPAP) decreased by a mean of 65 mm Hg (193%) in all participants[18] - Systemic Vascular Resistance (SVR) decreased by a mean of 32 WU (129%) in all participants[18] - Right Atrial Pressure (RAP) decreased by a mean of 31 mm Hg (292%) in all participants[18] Market Opportunity - The potential market for PH-HFrEF in the US is approximately 11 million, with about 300,000 cases of CpcPH (PVR≥3)[7]

Financial Performance - Total revenue for Q3 2025 reached $51242 million, compared to $40589 million in Q3 2024[11] - Advertising revenue in Q3 2025 was $50082 million, up from $39885 million in Q3 2024[11] - Family of Apps (FoA) revenue increased to $50772 million in Q3 2025 from $40319 million in Q3 2024[11] - Reality Labs (RL) revenue increased to $470 million in Q3 2025 from $270 million in Q3 2024[11] - Income from operations reached $20535 million in Q3 2025, compared to $17350 million in Q3 2024[11] - Net income for Q3 2025 was $2709 million, which includes a one-time, non-cash income tax charge of $15930 million[21, 22] - Excluding the one-time tax charge, Q3 2025 net income would have been $18640 million[22] User Metrics - Family Daily Active People (DAP) reached 343 billion in Q3 2025, compared to 329 billion in Q1 2025[35] - Family Average Revenue per Person (ARPP) was $1425 in Q3 2025[40] Advertising Metrics - Ad impressions delivered worldwide increased by 11% year-over-year in Q3 2025[46] - The average price per ad worldwide increased by 10% year-over-year in Q3 2025[50]

Financial Performance - Q3 2025 total revenues were $9957 million, a 18% year-over-year increase[21] - Q3 2025 Clear Aligner revenues reached $8058 million, up 24% year-over-year[21] - Q3 2025 Systems and Services revenues were $1899 million, a 06% year-over-year decrease[21] - Q3 2025 GAAP operating margin was 97%, a 69 percentage point decrease year-over-year[21] - Q3 2025 non-GAAP operating margin was 239%, a 18 percentage point increase year-over-year[98] Clear Aligner Segment - Q3 2025 worldwide Clear Aligner shipments totaled 6478K cases, a 49% year-over-year increase[22] - International Clear Aligner volume accounted for 52% of the total, while Americas accounted for 48%[28] - Clear Aligner average per case shipment price was $1245, down $30 year-over-year[88] - Over 63 million teens and kids have been treated with the Invisalign System to date[30] Systems and Services Segment - There are over 120K active iTero units globally, representing roughly half of the intraoral scanning global market[16, 62] - CAD/CAM and Services revenues represent approximately 50% of the Systems and Services business[68] Consumer and Marketing - Americas consumer campaigns delivered 25 billion impressions and 52 million unique website visitors[51] - APAC delivered 68 billion impressions and 20 million website visits in Q3[52]